BioCentury
ARTICLE | Company News

Novo's insulin degludec approved in Japan

September 29, 2012 1:17 AM UTC

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Tresiba insulin degludec to treat Type I and Type II diabetes. Novo Nordisk expects to launch Tresiba in Japan when pricing negotiations are completed. The long-acting insulin analog is under review in the U.S., Europe and Canada. ...